In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmion Bets That Europe is Alright for Some

Executive Summary

Pharmion is an in-licensing based company that has gone where a growing number of biotech companies fear to tread--to Europe. The firm is betting that the marketing infrastructure it has established there, plus regulatory expertise and willingness to take on some development work--even for products with dodgy or downright terrible pasts--will allow it to build a profitable business.

You may also be interested in...



MedPointe's Private Dilemma

MedPointe was born via the leveraged buy-out of an old, private pharmaceutical company, Carter-Wallace. Accepting financial strictures was part of the deal; the company must remain profitable. This increases the challenge for the "founders," seasoned pharma execs intent on leveraging the infrastructure they overhauled, to created an in-licensing based marketing powerhouse. Beyond competing with bigger pharma marketers, management's challenge remains bringing in new assets affordably.

Medeus: How To Find & Buy a Ready-Made Euro Infrastructure

Apax Partners paid $120 million for Elan's European sales and marketing infrastructure--renamed Medeus--to buy into the in-licensing game with a ready-made continent-wide commercial network. Few specialty companies can match its scope. But with little or no track record and a portfolio of mostly older, sometimes off-patent drugs, Medeus may nevertheless have to work hard to convince licensors to hand over their products.

At Reliant, Mario Tries for Alza II

Reliant Pharmaceuticals was created as an alternative to Big Pharma in marketing primary care products. But in-licensing market-ready products is expensive and primary-care sales forces expensive to maintain. With new CEO Ernie Mario, the company has now raised a huge amount of new money and will accelerate its efforts to in-license development stage products--a higher risk strategy, but the only way to ultimately create the margins necessary for sustainability.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV004811

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel